Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?
作者信息
de la Fouchardiere Christelle
机构信息
Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
出版信息
Ann Transl Med. 2019 Nov;7(21):601. doi: 10.21037/atm.2019.08.110.
Abstract
摘要
相似文献
1
Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?2019年治疗BRAFV600E转移性结直肠癌患者：希望之光？
Ann Transl Med. 2019 Nov;7(21):601. doi: 10.21037/atm.2019.08.110.
2
Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.恩考芬尼联合西妥昔单抗治疗BRAFV600E突变转移性结直肠癌患者的不良事件：BEACON CRC研究的深入分析
Clin Colorectal Cancer. 2023 Mar;22(1):59-66. doi: 10.1016/j.clcc.2022.12.003. Epub 2022 Dec 24.
3
Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer.BRAFV600E突变在亚洲结直肠癌患者中的临床意义
Int J Colorectal Dis. 2018 Sep;33(9):1173-1181. doi: 10.1007/s00384-018-3095-6. Epub 2018 Jun 4.
4
Prevalence and prognostic relevance of BrafV600E mutation in colorectal carcinomas from Kashmir (North India) valley.克什米尔（印度北部）山谷地区结直肠癌中BrafV600E突变的患病率及预后相关性
Mutagenesis. 2018 Sep 17;33(3):225-230. doi: 10.1093/mutage/gey008.
5
Encorafenib, binimetinib and cetuximab combined therapy for patients with mutant metastatic colorectal cancer.encorafenib、binimetinib 和 cetuximab 联合治疗携带突变的转移性结直肠癌患者。
Future Oncol. 2020 Feb;16(6):161-173. doi: 10.2217/fon-2019-0748.
6
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.恩考芬尼联合西妥昔单抗作为治疗后 V600E 突变转移性结直肠癌的新标准：BEACON 研究的更新生存结果和亚组分析。
J Clin Oncol. 2021 Feb 1;39(4):273-284. doi: 10.1200/JCO.20.02088.
7
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.CMS 依赖性 KRAS 和 BRAFV600E 突变对原发性结直肠癌的预后影响。
Ann Oncol. 2018 May 1;29(5):1227-1234. doi: 10.1093/annonc/mdy085.
8
BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.在日常临床实践中分析转移性结直肠癌（mCRC）患者的 BRAFV600E 突变：与临床特征的相关性及其对患者预后的影响。
PLoS One. 2013 Dec 18;8(12):e84604. doi: 10.1371/journal.pone.0084604. eCollection 2013.
9
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.MSI-H/dMMR 转移性结直肠癌患者接受免疫检查点抑制剂治疗时 BRAF V600E/RAS 突变与林奇综合征的相关性。
Oncologist. 2023 Sep 7;28(9):771-779. doi: 10.1093/oncolo/oyad082.
10
BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.BRAFV600E 免疫组化联合错配修复状态可预测结直肠癌患者的生存。
Mod Pathol. 2014 May;27(5):644-50. doi: 10.1038/modpathol.2013.200. Epub 2013 Oct 25.
本文引用的文献
1
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).随机试验伊立替康和西妥昔单抗与或无维莫非尼在 BRAF 突变转移性结直肠癌（SWOG S1406）。
J Clin Oncol. 2021 Feb 1;39(4):285-294. doi: 10.1200/JCO.20.01994. Epub 2020 Dec 23.
2
Population-based Screening for in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.基于人群的转移性结直肠癌筛查揭示了更高的患病率和较差的预后。
Clin Cancer Res. 2020 Sep 1;26(17):4599-4605. doi: 10.1158/1078-0432.CCR-20-1024. Epub 2020 Jun 22.
3
FOLFOXIRI Plus Panitumumab As First-Line Treatment of Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).FOLFOXIRI 联合帕尼单抗作为野生型转移性结直肠癌一线治疗：随机、开放标签、II 期 VOLFI 研究（AIO KRK0109）
J Clin Oncol. 2019 Dec 10;37(35):3401-3411. doi: 10.1200/JCO.19.01340. Epub 2019 Oct 14.
4
Characteristics of Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.突变型、缺陷型错配修复/ proficient 型错配修复、转移性结直肠癌的特征：287 例患者的多中心系列。
Oncologist. 2019 Dec;24(12):e1331-e1340. doi: 10.1634/theoncologist.2018-0914. Epub 2019 May 31.
5
Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis.转移性结直肠癌一线治疗后早期肿瘤退缩：一项荟萃分析。
Int J Clin Oncol. 2019 Mar;24(3):231-240. doi: 10.1007/s10147-019-01405-1. Epub 2019 Feb 4.
6
Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.BRAF 突变结直肠癌肝转移行肝切除术是否合理？：1497 例患者的多机构分析。
Ann Surg. 2020 Jan;271(1):147-154. doi: 10.1097/SLA.0000000000002968.
7
NCCN Guidelines Insights: Colon Cancer, Version 2.2018.NCCN 指南解读：结肠癌，第 2.2018 版。
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.
8
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹单抗治疗错配修复缺陷/微卫星高度不稳定转移性结直肠癌的持久临床获益。
J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
9
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.纳武利尤单抗治疗转移性DNA错配修复缺陷或微卫星高度不稳定结直肠癌患者（CheckMate 142）：一项开放标签、多中心、2期研究。
Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.
10
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
Zotero 插件